Inflammatory markers such as CRP and PTX3 are involved in both chronic and acute CAD phases highlighting the continuous nature of CAD pathophysiology.[4] Including ACS biomarkers in CAD risk assessment may enhance monitoring for patients at risk of progressing from chronic CAD to acute events. This evidence concerns the gene CRP and coronary artery disorder.